<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174719</url>
  </required_header>
  <id_info>
    <org_study_id>HAHes</org_study_id>
    <nct_id>NCT01174719</nct_id>
  </id_info>
  <brief_title>Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery</brief_title>
  <official_title>Phase 4 Study Comparing Albumin 5%, Hydroxyethylstrach 130/0.4 (6%) and Ringer Lactate for Volume Replacement During Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare three different regimens for volume replacement during
      cardiac surgery, e.g. Albumin 5%, Hydroxyethylstarch 130/0.4 (HES) and Ringer-Lactate (RL).

      Main Outcome parameters: chest tube drainage and coagulation parameters. The investigators
      hypothesis is that HES is as safe as Albumin, however less expensive. Whether RL is an even
      less expensive and as safe alternative has to be shown.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chest tube drainage</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>induction of anesthesia = baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit value</measure>
    <time_frame>induction of anesthesia = baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>induction of anesthesia = baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated clotting time</measure>
    <time_frame>induction of anesthesia = baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany)</measure>
    <time_frame>induction of anethesia = baseline</time_frame>
    <description>using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>average 1 hour on cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit value</measure>
    <time_frame>average 1 hour on cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany)</measure>
    <time_frame>average 1 hour on cardiopulmonary bypass</time_frame>
    <description>using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated clotting time</measure>
    <time_frame>average 1 hour on cardiopulmonary bypass</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>30 minutes after arrival ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit value</measure>
    <time_frame>30 minutes after arrival ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>30 minutes after arrival ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated clotting time</measure>
    <time_frame>30 minutes after arrival ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany)</measure>
    <time_frame>30 minutes after arrival ICU</time_frame>
    <description>using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin concentration</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit value</measure>
    <time_frame>24 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>24 hrs after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified thromboelastometry coagulation analysis (ROTEM, Pentapharm, Munich, Germany)</measure>
    <time_frame>24 hrs after surgery</time_frame>
    <description>using 3 activators: intrinsic ROTEM (InTEM, extrinsic ROTEM (ExTEM), finbrinogen ROTEM (FibTEM)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Hydroxyethylstarch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Humanalbumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ringer lactate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volume replacement</intervention_name>
    <description>Hydroxyethylstarch up to 50mL/kg/24 hrs</description>
    <arm_group_label>Hydroxyethylstarch</arm_group_label>
    <other_name>Voluven</other_name>
    <other_name>HES 130/0.4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humanalbumin 5%</intervention_name>
    <description>Humanalbumin 5% up to 50 mL/kg/24 hours</description>
    <arm_group_label>Humanalbumin</arm_group_label>
    <other_name>Humanalbumin 5% Baxter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>volume replacement</intervention_name>
    <description>up 10 50mL/kg/24 hours</description>
    <arm_group_label>Ringer lactate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Valve replacement

          -  Coronary bypass surgery

        Exclusion Criteria:

          -  Severe left ventricular dysfunction

          -  Coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva M Base, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Eva M. Base</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hydroxyethylstarch</keyword>
  <keyword>Humanalbumin</keyword>
  <keyword>Ringer Lactate</keyword>
  <keyword>patients undergoing cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

